We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+27.77%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$8.73B
AUM Growth
+$1.49B
Cap. Flow
+$225M
Cap. Flow %
2.57%
Top 10 Hldgs %
31.85%
Holding
234
New
17
Increased
80
Reduced
68
Closed
12

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$143M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$63.9M
3
MRSN
Mersana Therapeutics
MRSN
+$42.8M
4
DXCM icon
DexCom
DXCM
+$32.7M
5
ABBV icon
AbbVie
ABBV
+$32.5M

Top Sells

Rank Stock Value
1
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$154M
2
HALO icon
Halozyme
HALO
+$51.2M
3
CRL icon
Charles River Laboratories
CRL
+$49.6M
4
CDNA icon
CareDx
CDNA
+$44.7M
5
MDT icon
Medtronic
MDT
+$40.8M

Sector Composition

Rank Sector Weight
1 Healthcare 95.9%
2 Technology 0.6%
3 Industrials 0.33%
4 Financials 0.11%
5 Consumer Discretionary 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IPGP icon
176
IPG Photonics
IPGP
$3.89B
$526K 0.01%
2,350
-350
-13% -$70.1K
ST icon
177
Sensata Technologies
ST
$6.65B
$522K 0.01%
9,900
– –
BR icon
178
Broadridge
BR
$17.2B
$521K 0.01%
3,400
– –
IQV icon
179
IQVIA
IQV
$34.7B
$520K 0.01%
2,900
– –
VRSK icon
180
Verisk Analytics
VRSK
$26.4B
$517K 0.01%
2,489
– –
ENTG icon
181
Entegris
ENTG
$19.7B
$509K 0.01%
5,300
-2,000
-27% -$175K
TRU icon
182
TransUnion
TRU
$14.8B
$506K 0.01%
5,096
– –
PAYX icon
183
Paychex
PAYX
$40.4B
$503K 0.01%
5,400
– –
RVTY icon
184
Revvity
RVTY
$12.3B
$502K 0.01%
3,500
-1,300
-27% -$173K
CTLT
185
DELISTED
CATALENT, INC.
CTLT
$489K 0.01%
4,700
-1,000
-18% -$96.9K
FAST icon
186
Fastenal
FAST
$54B
$488K 0.01%
20,000
– –
TYL icon
187
Tyler Technologies
TYL
$12.2B
$480K 0.01%
1,100
-425
-28% -$175K
MTD icon
188
Mettler-Toledo International
MTD
$26.8B
$479K 0.01%
420
-280
-40% -$307K
GGG icon
189
Graco
GGG
$12.9B
$478K 0.01%
6,600
-3,100
-32% -$207K
EA icon
190
Electronic Arts
EA
$52.4B
$470K 0.01%
3,270
-1,400
-30% -$180K
MKTX icon
191
MarketAxess Holdings
MKTX
$4.15B
$469K 0.01%
822
– –
WAB icon
192
Wabtec
WAB
$51.1B
$468K 0.01%
6,400
– –
JD icon
193
JD.com
JD
$40.8B
$466K 0.01%
5,300
-3,400
-39% -$284K
SBUX icon
194
Starbucks
SBUX
$118B
$464K 0.01%
4,334
– –
CSGP icon
195
CoStar Group
CSGP
$11.3B
$462K 0.01%
5,000
-2,000
-29% -$175K
LYV icon
196
Live Nation Entertainment
LYV
$41.2B
$456K 0.01%
6,200
– –
VRSN icon
197
VeriSign
VRSN
$25.3B
$454K 0.01%
2,100
– –
ANSS
198
DELISTED
Ansys
ANSS
$451K 0.01%
1,240
-562
-31% -$188K
STZ icon
199
Constellation Brands
STZ
$22.2B
$451K 0.01%
2,059
– –
POOL icon
200
Pool Corp
POOL
$6.7B
$447K 0.01%
1,200
-1,000
-45% -$349K
6 7
8
9 10

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
AI
Advent International Boston, Massachusetts $4.24B AUM 4.24% 1-Year Est. Return

Bellevue Group's Q4 2020 Portfolio in Review

As of Q4 2020, Bellevue Group held 234 positions worth $8.73B, up 21% from $7.24B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Bellevue Group's Q4 2020 filing shows 17 new, 80 increased, 68 reduced and 12 closed positions. Its largest new stake was Mersana Therapeutics: 77,040 shares worth $51.3M. The largest sale was MyoKardia, Inc. Common Stock, an estimated $154M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 96% a quarter earlier, followed by Technology and Industrials.

  • Bellevue Group's largest Q4 2020 buy was Mersana Therapeutics: 77,040 shares worth $51.3M.
  • Bellevue Group added most to Biogen in Q4 2020, an estimated $143M increase.
  • Bellevue Group's biggest Q4 2020 reduction was Halozyme, cutting an estimated $51.2M.
  • Bellevue Group fully exited MyoKardia, Inc. Common Stock in Q4 2020, selling an estimated $154M.
  • Bellevue Group's ten largest holdings make up 32% of its $8.73B portfolio in Q4 2020.
  • Bellevue Group opened 17 new positions and closed 12 in Q4 2020.
  • Bellevue Group's portfolio value rose 21% quarter-over-quarter to $8.73B.

Based on Bellevue Group's 13F filing for Q4 2020, filed 16 Feb 2021.